Navigation Links
Jennerex and Green Cross Announce Publication of Positive Clinical Data of JX-594 in Combination With Sorafenib in Advanced Liver Cancer
Date:4/20/2011

ive tumor response has been demonstrated in a variety of cancers including liver, colon, kidney, lung and melanoma.

Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize JX-594 in Europe and neighboring countries. Green Cross Corporation holds an exclusive license to develop and commercialize JX-594 in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize JX-594 in China.

About Liver Cancer and Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer-related deaths world-wide with about 660,000 patients dying from the disease annually. Most HCC cases develop on the background of chronic liver cirrhosis; in regions with the highest incidence of HCC, East Asian and African countries, the majority of cases are related to hepatitis B; in developed Western countries and Japan the disease is commonly related to hepatitis C, heavy alcohol consumption and non-alcoholic fatty liver due to metabolic syndromes such as diabetes and obesity. There is accumulating evidence that the incidence of HCC is increasing in Western countries. Despite recent advances, the treatment of advanced HCC remains a significant unmet medical need with a median expected survival under current therapies of less than one year.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish o
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
2. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
3. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
4. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
5. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
6. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
7. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
8. Jennerex Announces Presentations at Upcoming Conferences
9. Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
10. Jennerex Appoints Lara Longpre to Chief Operating Officer
11. Jennerex Names Dr. Mark P. Backer as Senior Vice President of Technical Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Armada Health Care ... the new Armada corporate website ( www.armadahealthcare.com ).  ... Armada,s unique and first-to-market services and its position ... on the specialty pharmacy industry. The ... the Armada business model in delivering an extensive ...
(Date:5/21/2013)... CLARA, Calif. , May 21, 2013 ... game-changing embedded-ultrasound platform, today announced the introduction ... that allows complete network-based communications with all ... its latest embedded-ultrasound technology, including this new ... Sao Paulo, Brazil from ...
(Date:5/21/2013)... 21, 2013 Hurel Corporation ("Hurel"), a world-leading ... assay platforms, today announced the appointment of ... Company,s Board of Directors. Dr. MacDonald is the former ... Research Institute ("SPRI"), which was the pharmaceutical development arm ... & Co. in 2009. Over a career ...
Breaking Medicine Technology:Armada Announces New Corporate Website to Showcase Expanded Services to Specialty Pharmacy Marketplace 2Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2
(Date:5/21/2013)... Gray HealthDay Reporter , , TUESDAY, May 21 ... was once next to impossible, but a new study ... screening with low-dose CT scans may help spot the ... patients considered at the greatest risk for lung cancer, ... getting CT scans and follow-up biopsies to confirm the ...
(Date:5/21/2013)... 2013 Not all treatments are effective ... Borderline Personality Disorder (BPD) and addiction. Dialectical Behavior Therapy ... successful for the treatment of both BPD and substance ... Ph.D., clinical director of Clearview Women’s Center for ... provide attendees of the West Coast Symposium on Addictive ...
(Date:5/21/2013)... brain tumor cells that uses a modified poliovirus is ... the proper dose level, researchers at Duke Cancer Institute ... in an ongoing phase 1 study, capitalizes on the ... that work like magnets drawing the poliovirus, which then ... therapy, known as PVSRIPO, uses an engineered form of ...
(Date:5/21/2013)... Austin, TX (PRWEB) May 21, 2013 As ... be heading off to summer camp or beginning practice ... physical exam is required before camp or sporting activities can ... is offering an affordable option for youth sports or ... the physical, MedSpring’s on-site doctors will review a child’s medical ...
(Date:5/21/2013)... Urban elementary school children with poorly controlled asthma ... academically, new research indicates. "In our sample ... found that compromised lung function corresponded with both ... study author Daphne Koinis-Mitchell, an associate professor ... Alpert Medical School in Providence, R.I. Koinis-Mitchell, ...
Breaking Medicine News(10 mins):Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 2Health News:Study Supports Using Low-Dose CT Scans to Spot Early Lung Cancer 3Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 2Health News:Clearview Treatment Programs Clinical Director to Present on DBT and Substance Abuse at WCSAD 3Health News:Poliovirus vaccine trial shows early promise for recurrent glioblastoma 2Health News:MedSpring Offers Affordable Youth Physicals for $29 2Health News:Sleepless Nights May Hurt School Performance of Kids With Asthma 2
... There is skepticism about Canada’s Public health care system, with ... causing a lot of ripples amongst people. The decade ... way to revive the ailing healthcare.// ,Canada health ... especially elective surgeries. Several Canadians even explore the option of ...
... Toronto: Health officials have flashed a warning to be on ... cases reported spreads through Toronto. ,Since November, nearly 167 ... public health department, called as a whooping cough with under ... are vaccinated against the disease, the vaccine is not known ...
... of beauty are most commonly blamed for lowering self-esteem ... trend, // a lot of marketing companies (including Dove) ... messages in an effective way. ,A new ... more likely to lower the onlooker’s self esteem, contrary ...
... Disorder (ADHD), Ritalin (Novartis AG) and Adderall (Shire Pharmaceuticals) ... the safety and side effects // of the drug. ... reports of the U.S. advisory panel, which stated that ... drugs. There is a possibility of sudden death, heart ...
... the universities of Notre Dame, Rochester (NY) and Catholic ... the way parents handle everyday conflicts between themselves affects ... the impact of parental behavior on the psyche of ... of the journal Child Development. ,"A useful analogy ...
... recorded a total of 91 suicides in 2005 through what ... from 55 deaths the previous year, according to a recent ... tripled from 2003, the first year the National Police Agency ... been widespread throughout Japan in recent years. Users share death ...
Cached Medicine News:Health News:Parental Conflicts Lead To Emotional Insecurity In Children 2
A blotter fit for use with the incredible new Criterion precast gel system, the Criterion blotter combines excellent blotting efficiency with the flexibility of the Trans-Blot system and the ease-of-...
... Western Blot analysis ... Blot Analyzer for many applications including the ... of infectious diseases such as viruses and ... screening of allergies and other application areas ...
... Advantages of using the Antigen-Antibody Pens-Using ... designed and developed specialized fountain pens, called ... deliver or write/mark the blotting membranes in ... specially formulated antigen-bonded colored dyes helps to ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
Medicine Products: